Advertisement
Screener

PUMA BIOTECHNOLOGY, INC. (PBYI) Operating Expenses

2.8 / 5 stars · 68/120 Roast Me

PUMA BIOTECHNOLOGY, INC. Operating Expenses

PUMA BIOTECHNOLOGY, INC. (PBYI) reported Operating Expenses of $70.02 million for the 3-month period ending 2021-06-30, per its 10-Q filed 2021-08-05.

Discontinued › Expense Statement › Operating Expenses

us-gaap:OperatingExpenses · last filed 2021-08-05

  • PUMA BIOTECHNOLOGY, INC. operating expenses for the quarter ending 2021-06-30 was $70.02M, a 10.34% increase year-over-year.
  • PUMA BIOTECHNOLOGY, INC. operating expenses for the quarter ending 2021-03-31 was $78.02M, a 19.18% increase year-over-year.
  • PUMA BIOTECHNOLOGY, INC. operating expenses for the quarter ending 2020-12-31 was $63.71M, a 11.01% decline year-over-year.
  • PUMA BIOTECHNOLOGY, INC. operating expenses for the quarter ending 2020-09-30 was $62.88M, a 11.18% decline year-over-year.
  • PUMA BIOTECHNOLOGY, INC. operating expenses for fiscal 2020 was $255.51M, a 17.92% decline from fiscal 2019.
  • PUMA BIOTECHNOLOGY, INC. operating expenses for fiscal 2019 was $311.31M, a 9.94% decline from fiscal 2018.
  • PUMA BIOTECHNOLOGY, INC. operating expenses for fiscal 2018 was $345.65M, a 7.99% increase from fiscal 2017.
  • PUMA BIOTECHNOLOGY, INC. operating expenses for fiscal 2017 was $320.07M, a 15.72% increase from fiscal 2016.
Period endOperating Expenses 3 monthOperating Expenses 3 month as first filedOperating Expenses 4 monthOperating Expenses 6 monthOperating Expenses 6 month as first filedOperating Expenses 9 monthOperating Expenses 9 month as first filedOperating Expenses 12 monthOperating Expenses 12 month as first filedOperating Expenses 16 monthOperating Expenses 18 monthOperating Expenses 21 monthOperating Expenses 25 monthOperating Expenses 27 monthOperating Expenses 30 monthOperating Expenses 33 monthOperating Expenses 36 monthOperating Expenses 39 monthOperating Expenses 42 monthOperating Expenses 45 monthOperating Expenses 48 month
2021-06-30$70.02M
10-Q · filed 2021-08-05
$148.14M
10-Q · filed 2021-08-05
$211.75M
derived: sum of 3 quarters · filed 2021-08-05
$274.63M
derived: sum of 4 quarters · filed 2021-08-05
2021-03-31$78.02M
10-Q · filed 2021-05-06
$141.73M
derived: sum of 2 quarters · filed 2021-05-06
$204.61M
derived: sum of 3 quarters · filed 2021-05-06
$268.07M
derived: sum of 4 quarters · filed 2021-08-05
2020-12-31$63.71M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01
$126.59M
derived: sum of 2 quarters · filed 2021-03-01
$190.04M
derived: sum of 3 quarters · filed 2021-08-05
$255.51M
10-K · filed 2021-03-01
2020-09-30$62.88M
10-Q · filed 2020-11-05
$126.34M
derived: sum of 2 quarters · filed 2021-08-05
$191.81M
10-Q · filed 2020-11-05
$263.39M
derived: sum of 4 quarters · filed 2021-08-05
2020-06-30$63.45M
10-Q · filed 2021-08-05
$128.92M
10-Q · filed 2021-08-05
$200.51M
derived: sum of 3 quarters · filed 2021-08-05
$271.31M
derived: sum of 4 quarters · filed 2021-08-05
2020-03-31$65.47M
10-Q · filed 2021-05-06
$137.06M
derived: sum of 2 quarters · filed 2021-05-06
$207.85M
derived: sum of 3 quarters · filed 2021-05-06
$287.55M
derived: sum of 4 quarters · filed 2021-05-06
2019-12-31$71.59M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01
$142.39M
derived: sum of 2 quarters · filed 2021-03-01
$222.09M
derived: sum of 3 quarters · filed 2021-03-01
$311.31M
10-K · filed 2021-03-01
$311.36M
10-K · filed 2020-02-28
2019-09-30$70.80M
10-Q · filed 2020-11-05
$150.50M
derived: sum of 2 quarters · filed 2020-11-05
$239.72M
10-Q · filed 2020-11-05
$329.33M
derived: sum of 4 quarters · filed 2021-03-01
2019-06-30$79.70M
10-Q · filed 2020-08-06
$168.92M
10-Q · filed 2020-08-06
$258.53M
derived: sum of 3 quarters · filed 2021-03-01
$332.44M
derived: sum of 4 quarters · filed 2021-03-01
2019-03-31$89.22M
10-Q · filed 2020-05-07
$178.84M
derived: sum of 2 quarters · filed 2021-03-01
$252.75M
derived: sum of 3 quarters · filed 2021-03-01
$344.96M
derived: sum of 4 quarters · filed 2021-03-01
2018-12-31$89.62M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01
$163.53M
derived: sum of 2 quarters · filed 2021-03-01
$255.74M
derived: sum of 3 quarters · filed 2021-03-01
$345.65M
10-K · filed 2021-03-01
$345.66M
10-K · filed 2019-03-01
2018-09-30$73.91M
10-Q · filed 2019-11-07
$166.12M
derived: sum of 2 quarters · filed 2019-11-07
$256.03M
10-Q · filed 2019-11-07
$341.20M
derived: sum of 4 quarters · filed 2020-02-28
2018-06-30$92.21M
10-Q · filed 2019-08-09
$182.12M
10-Q · filed 2019-08-09
$267.30M
derived: sum of 3 quarters · filed 2020-02-28
$350.81M
derived: sum of 4 quarters · filed 2020-02-28
2018-03-31$89.91M
10-Q · filed 2019-05-10
$175.08M
derived: sum of 2 quarters · filed 2020-02-28
$258.60M
derived: sum of 3 quarters · filed 2020-02-28
$336.78M
derived: sum of 4 quarters · filed 2020-02-28
2017-12-31$85.17M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28
$168.69M
derived: sum of 2 quarters · filed 2020-02-28
$246.87M
derived: sum of 3 quarters · filed 2020-02-28
$320.07M
10-K · filed 2020-02-28
2017-09-30$83.52M
10-Q · filed 2018-11-05
$161.70M
derived: sum of 2 quarters · filed 2018-11-05
$234.90M
10-Q · filed 2018-11-05
$307.77M
derived: sum of 4 quarters · filed 2019-03-01
2017-06-30$78.18M
10-Q · filed 2018-08-09
$151.38M
10-Q · filed 2018-08-09
$224.25M
derived: sum of 3 quarters · filed 2019-03-01
$290.25M
derived: sum of 4 quarters · filed 2019-03-01
2017-03-31$73.20M
10-Q · filed 2018-05-10
$146.07M
derived: sum of 2 quarters · filed 2019-03-01
$212.07M
derived: sum of 3 quarters · filed 2019-03-01
$278.55M
derived: sum of 4 quarters · filed 2019-03-01
2016-12-31$72.87M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01
$138.87M
derived: sum of 2 quarters · filed 2019-03-01
$205.35M
derived: sum of 3 quarters · filed 2019-03-01
$276.60M
10-K · filed 2019-03-01
2016-09-30$66.00M
10-Q · filed 2017-11-09
$132.48M
derived: sum of 2 quarters · filed 2017-11-09
$203.73M
10-Q · filed 2017-11-09
$265.76M
derived: sum of 4 quarters · filed 2018-03-09
2016-06-30$66.48M
10-Q · filed 2017-08-09
$137.73M
10-Q · filed 2017-08-09
$199.76M
derived: sum of 3 quarters · filed 2018-03-09
$260.50M
derived: sum of 4 quarters · filed 2018-03-09
2016-03-31$71.25M
10-Q · filed 2017-05-10
$133.28M
derived: sum of 2 quarters · filed 2018-03-09
$194.01M
derived: sum of 3 quarters · filed 2018-03-09
$258.93M
derived: sum of 4 quarters · filed 2018-03-09
2015-12-31$62.03M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09
$122.77M
derived: sum of 2 quarters · filed 2018-03-09
$187.68M
derived: sum of 3 quarters · filed 2018-03-09
$240.28M
10-K · filed 2018-03-09
2015-09-30$60.73M
10-Q · filed 2016-11-09
$125.65M
derived: sum of 2 quarters · filed 2016-11-09
$178.25M
10-Q · filed 2016-11-09
$225.84M
derived: sum of 4 quarters · filed 2017-03-01
2015-06-30$64.91M
10-Q · filed 2016-08-09
$117.51M
10-Q · filed 2016-08-09
$165.10M
derived: sum of 3 quarters · filed 2017-03-01
$201.06M
derived: sum of 4 quarters · filed 2017-03-01
2015-03-31$52.60M
10-Q · filed 2016-05-10
$100.19M
derived: sum of 2 quarters · filed 2017-03-01
$136.15M
derived: sum of 3 quarters · filed 2017-03-01
$175.06M
derived: sum of 4 quarters · filed 2017-03-01
2014-12-31$47.59M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01
$83.55M
derived: sum of 2 quarters · filed 2017-03-01
$122.46M
derived: sum of 3 quarters · filed 2017-03-01
$142.28M
10-K · filed 2017-03-01
2014-09-30$35.96M
10-Q · filed 2015-11-09
$74.86M
derived: sum of 2 quarters · filed 2015-11-09
$94.68M
10-Q · filed 2015-11-09
$110.67M
derived: sum of 4 quarters · filed 2016-02-29
$234.13M
10-Q · filed 2014-11-10
2014-06-30$38.91M
10-Q · filed 2015-08-10
$58.72M
10-Q · filed 2015-08-10
$74.71M
derived: sum of 3 quarters · filed 2016-02-29
$89.04M
derived: sum of 4 quarters · filed 2016-02-29
$198.17M
10-Q · filed 2014-08-11
2014-03-31$19.82M
10-Q · filed 2015-05-11
$35.81M
derived: sum of 2 quarters · filed 2016-02-29
$50.14M
derived: sum of 3 quarters · filed 2016-02-29
$62.85M
derived: sum of 4 quarters · filed 2016-02-29
$159.27M
10-Q · filed 2014-05-12
2013-12-31$15.99M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29
$30.32M
derived: sum of 2 quarters · filed 2016-02-29
$43.03M
derived: sum of 3 quarters · filed 2016-02-29
$54.83M
10-K · filed 2016-02-29
$139.45M
10-K · filed 2014-03-03
2013-09-30$14.33M
10-Q · filed 2014-11-10
$27.04M
derived: sum of 2 quarters · filed 2014-11-10
$38.84M
10-Q · filed 2014-11-10
$60.79M
derived: sum of 4 quarters · filed 2015-03-02
$123.46M
10-Q · filed 2013-11-12
2013-06-30$12.71M
10-Q · filed 2014-08-11
$24.51M
10-Q · filed 2014-08-11
$46.46M
derived: sum of 3 quarters · filed 2015-03-02
$72.33M
derived: sum of 4 quarters · filed 2015-03-02
$109.13M
10-Q · filed 2013-08-06
2013-03-31$11.81M
10-Q · filed 2014-05-12
$33.75M
derived: sum of 2 quarters · filed 2015-03-02
$59.63M
derived: sum of 3 quarters · filed 2015-03-02
$74.40M
derived: sum of 4 quarters · filed 2015-03-02
$96.42M
10-Q · filed 2013-05-09
2012-12-31$21.95M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02
$47.82M
derived: sum of 2 quarters · filed 2015-03-02
$62.60M
derived: sum of 3 quarters · filed 2015-03-02
$74.45M
10-K · filed 2015-03-02
$84.61M
10-K · filed 2013-04-01
2012-09-30$25.87M
10-Q · filed 2013-11-12
$25.87M
10-Q · filed 2012-11-14
$40.65M
derived: sum of 2 quarters · filed 2013-11-12
$52.50M
10-Q · filed 2013-11-12
$52.50M
10-Q · filed 2012-11-14
$62.29M
derived: sum of 4 quarters · filed 2014-03-03
$62.67M
10-Q · filed 2012-11-14
2012-06-30$14.78M
10-Q · filed 2013-08-06
$14.78M
10-Q · filed 2012-08-14
$26.63M
10-Q · filed 2013-08-06
$26.63M
10-Q · filed 2012-08-14
$36.41M
derived: sum of 3 quarters · filed 2014-03-03
$36.75M
derived: sum of 4 quarters · filed 2014-03-03
$36.79M
10-Q · filed 2012-08-14
2012-03-31$11.85M
10-Q · filed 2013-05-09
$11.85M
10-Q · filed 2012-05-15
$21.64M
derived: sum of 2 quarters · filed 2014-03-03
$21.97M
derived: sum of 3 quarters · filed 2014-03-03
$22.01M
derived: sum of 4 quarters · filed 2014-03-03
$22.02M
10-Q · filed 2012-05-15
2011-12-31$9.78M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03
$10.12M
derived: sum of 2 quarters · filed 2014-03-03
$10.15M
derived: sum of 3 quarters · filed 2014-03-03
$10.16M
10-K · filed 2014-03-03
$10.16M
10-K · filed 2012-03-29
$10.16M
10-K · filed 2012-03-29
2011-09-30$333.93K
10-Q · filed 2012-11-14
$368.20K
derived: sum of 2 quarters · filed 2012-11-14
$372.14K
10-Q · filed 2012-11-14
$379.07K
10-Q · filed 2011-11-14
2011-06-30$34.27K
10-Q · filed 2012-08-14
$38.21K
10-Q · filed 2012-08-14
$45.21K
derived: sum of 3 quarters · filed 2013-04-01
$51.84K
derived: sum of 4 quarters · filed 2013-04-01
2011-03-31$3.94K
10-Q · filed 2012-05-15
$10.94K
derived: sum of 2 quarters · filed 2013-04-01
$17.57K
derived: sum of 3 quarters · filed 2013-04-01
2010-12-31$7.00K
10-K · filed 2013-04-01
$6.93K
10-K · filed 2012-03-29
$13.63K
derived: sum of 2 quarters · filed 2013-04-01
2010-09-30$6.63K
10-Q · filed 2011-11-14
$6.63K
10-Q · filed 2011-11-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
ARVINAS, INC. (ARVN)United States$0.510B58.38
CAPRICOR THERAPEUTICS, INC. (CAPR)United States$0.499B-10.81
Evolus, Inc. (EOLS)United States$0.519B-13.32
Ovid Therapeutics Inc. (OVID)United States$0.487B-14.41
CRESCENT BIOPHARMA, INC. (CBIO)United States$0.529B-5.20
ASSEMBLY BIOSCIENCES, INC. (ASMB)United States$0.481B-13,053.96
Indaptus Therapeutics, Inc. (INDP)United States$0.537B
MapLight Therapeutics, Inc. (MPLT)United States$0.459B-7.10
Quoin Pharmaceuticals Ltd. (QNRX)$0.443B-17.85
Phathom Pharmaceuticals, Inc. (PHAT)United States$0.572B-8.76